| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1038/NRC2054 |
| P698 | PubMed publication ID | 18034184 |
| P50 | author | Olufunmilayo Olopade | Q7088836 |
| P2093 | author name string | James D Fackenthal | |
| P2860 | cites work | A Collaborative Survey of 80 Mutations in the BRCA1 Breast and Ovarian Cancer Susceptibility Gene | Q56438525 |
| Risk of Endometrial Carcinoma Associated with BRCA Mutation | Q56928449 | ||
| Mutational analyses ofBRCA1 andBRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer | Q57200567 | ||
| Gene-Expression Profiles in Hereditary Breast Cancer | Q57240053 | ||
| Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up ofBRCA1Mutation Carriers | Q57250696 | ||
| Population-based study of risk of breast cancer in carriers of BRCA2 mutation | Q57250754 | ||
| Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation | Q57266937 | ||
| Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer Patients | Q57274822 | ||
| Polygenic Inherited Predisposition to Breast Cancer | Q57306194 | ||
| BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes | Q57309394 | ||
| Prevalence and Predictors ofBRCA1andBRCA2Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years | Q57634485 | ||
| Spectrum and prevalence ofBRCA1 andBRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening | Q57781606 | ||
| An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women | Q57903110 | ||
| Three per cent of Norwegian Ovarian Cancers are caused by BRCA1 1675delA or 1135insA | Q58048715 | ||
| Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer | Q59238528 | ||
| RNA analysis of eightBRCA1andBRCA2unclassified variants identified in breast/ovarian cancer families from Spain | Q59274489 | ||
| BRCA2 germ-line mutations in Spanish male breast cancer patients | Q59312565 | ||
| Differential Contributions ofBRCA1andBRCA2to Early-Onset Breast Cancer | Q61647812 | ||
| Mutational analysis of theBRCA1 gene in 30 Czech ovarian cancer patients | Q61896436 | ||
| Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany | Q61970381 | ||
| Germline BRCA1 185delAG mutations in Jewish women with breast cancer | Q71107825 | ||
| BRCA2 germline mutations in male breast cancer cases and breast cancer families | Q71167609 | ||
| Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core | Q71532382 | ||
| Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 | Q71614580 | ||
| Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene | Q71955901 | ||
| Unusual case of Smith-Lemli-Opitz syndrome "type II" | Q72306549 | ||
| The founder effect and deleterious genes | Q72377426 | ||
| The distribution of human genetic diversity: a comparison of mitochondrial, autosomal, and Y-chromosome data | Q22066141 | ||
| Genetic traces of ancient demography | Q22066179 | ||
| Mitochondrial DNA and human evolution | Q22122407 | ||
| Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients | Q24170410 | ||
| Communication of the position of exon-exon junctions to the mRNA surveillance machinery by the protein RNPS1 | Q24291664 | ||
| Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 | ||
| mtDNA and the origin of the Icelanders: deciphering signals of recent population history | Q24539114 | ||
| The matrilineal ancestry of Ashkenazi Jewry: portrait of a recent founder event | Q24540769 | ||
| Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan | Q24611839 | ||
| Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer | Q24796354 | ||
| How many more breast cancer predisposition genes are there? | Q24800566 | ||
| Genetic structure in four West African population groups | Q24814136 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 | Q28115843 | ||
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic | Q28211970 | ||
| Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 | Q28212276 | ||
| Human demographic history: refining the recent African origin model | Q28214983 | ||
| Genetic analysis of African populations: human evolution and complex disease | Q28216772 | ||
| Genetic structure of human populations | Q28218564 | ||
| The "portrait" of hereditary breast cancer | Q28238725 | ||
| Reconstructing human origins in the genomic era | Q28259027 | ||
| Characterization of BRCA1 and BRCA2 mutations in a large United States sample | Q28383993 | ||
| Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients | Q28384196 | ||
| The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews | Q28387376 | ||
| Estimating African American admixture proportions by use of population-specific alleles | Q29616216 | ||
| Identification of the breast cancer susceptibility gene BRCA2 | Q29616290 | ||
| Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium | Q29619206 | ||
| Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group | Q73108544 | ||
| Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families | Q73282154 | ||
| Prevalence of BRCA1 founder mutations in western Poland | Q73347751 | ||
| Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases | Q73549639 | ||
| Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family | Q73670657 | ||
| Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients | Q74113697 | ||
| Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study | Q74157664 | ||
| BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases | Q74449532 | ||
| Frequency of breast cancer attributable to BRCA1 in a population-based series of American women | Q74449603 | ||
| BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing | Q74525381 | ||
| One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden | Q75344773 | ||
| Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania-Kujawy region of Poland | Q76384541 | ||
| The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study | Q77639218 | ||
| Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer | Q77845970 | ||
| The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons | Q78410743 | ||
| Constraints for genetic association studies imposed by attributable fraction and familial risk | Q79165739 | ||
| Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing | Q79214311 | ||
| Trends in breast cancer by race and ethnicity | Q80259578 | ||
| Significant contribution of germline BRCA2 rearrangements in male breast cancer families | Q81019007 | ||
| BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study | Q81078213 | ||
| Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry | Q81370600 | ||
| Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer | Q81644523 | ||
| Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families | Q81677599 | ||
| Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France | Q81736126 | ||
| A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques | Q81841619 | ||
| Breast cancer predisposing alleles in Poland | Q81892020 | ||
| Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families | Q93945614 | ||
| Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer | Q95721725 | ||
| The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews | Q29619407 | ||
| Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India | Q33259252 | ||
| Frequency of BRCA1 mutation 5382insC in German breast cancer patients. | Q33853807 | ||
| Variation in cancer risks, by mutation position, in BRCA2 mutation carriers | Q34044197 | ||
| The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation | Q34108442 | ||
| Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer | Q34113283 | ||
| A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes | Q34115258 | ||
| Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations | Q34129787 | ||
| Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing | Q34144140 | ||
| BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer | Q34145544 | ||
| MtDNA evidence for a genetic bottleneck in the early history of the Ashkenazi Jewish population | Q34289752 | ||
| Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2 | Q34384153 | ||
| Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study | Q34385784 | ||
| A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes | Q34385903 | ||
| Haplotype trees and modern human origins. | Q34478613 | ||
| Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource | Q34480599 | ||
| Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study | Q34498634 | ||
| A high proportion of founder BRCA1 mutations in Polish breast cancer families | Q34548008 | ||
| Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium | Q34724404 | ||
| Linkage disequilibrium mapping in isolated populations: the example of Finland revisited | Q34754002 | ||
| Breast cancer genetics in African Americans | Q35030244 | ||
| Racial differences in genetic factors associated with breast cancer | Q35115280 | ||
| Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado | Q35184354 | ||
| Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. | Q35248795 | ||
| Large genomic deletions inactivate the BRCA2 gene in breast cancer families | Q35447232 | ||
| Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women | Q36176860 | ||
| Prevalence of BRCA mutations and founder effect in high-risk Hispanic families | Q36200696 | ||
| Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma | Q36338003 | ||
| Germline BRCA2 mutations in men with breast cancer | Q36431527 | ||
| BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer | Q36617295 | ||
| The BOADICEA model of genetic susceptibility to breast and ovarian cancer | Q36695832 | ||
| BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study | Q36696220 | ||
| A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer | Q38459569 | ||
| Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000. | Q38469992 | ||
| The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim | Q38892074 | ||
| Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women? | Q39011572 | ||
| Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study | Q39605778 | ||
| BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy | Q40345138 | ||
| Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations | Q40718941 | ||
| BRCA1 dysfunction in sporadic basal-like breast cancer | Q42502209 | ||
| Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families | Q42781699 | ||
| Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies | Q43073201 | ||
| Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations | Q43073772 | ||
| Evidence for a BRCA1 founder mutation in families of West African ancestry | Q43218569 | ||
| Hereditary ovarian cancer in Poland. | Q43683502 | ||
| BRCA2 germline mutations in male breast cancer patients in the Polish population | Q43840341 | ||
| The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. | Q43974233 | ||
| Inherited BRCA2 mutations in African Americans with breast and/or ovarian cancer: a study of familial and early onset cases | Q44243698 | ||
| BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic | Q44254509 | ||
| A faux 3'-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay | Q45138843 | ||
| BRCA1 variants in a family study of African-American and Latina women | Q46574954 | ||
| BRCA1 and BRCA2 mutations in women from Shanghai China | Q47197575 | ||
| Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations | Q47595985 | ||
| Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations | Q47696751 | ||
| BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer | Q47805719 | ||
| Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation | Q48070015 | ||
| Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects | Q48229800 | ||
| Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer | Q48610385 | ||
| Testing for BRCA1 mutations: a cost-effectiveness analysis | Q50708409 | ||
| BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. | Q52897865 | ||
| Assessing BRCA carrier probabilities in extended families. | Q52997805 | ||
| Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene? | Q54642509 | ||
| Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. | Q54719480 | ||
| Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. | Q54765466 | ||
| Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. | Q55067014 | ||
| The Exon 13 Duplication in the BRCA1 Gene Is a Founder Mutation Present in Geographically Diverse Populations | Q56438043 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 937-948 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations | |
| P478 | volume | 7 |
| Q33948754 | A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival |
| Q30705168 | A Frailty-Model-Based Method for Estimating Age-Dependent Penetrance from Family Data |
| Q38844517 | A Review of Whole-Exome Sequencing Efforts Toward Hereditary Breast Cancer Susceptibility Gene Discovery |
| Q93013646 | A computational approach to the study of interactions between proteins and miR10-b, miR-335, and miR-21 involved in breast cancer |
| Q40379657 | A framework for how environment contributes to cancer risk. |
| Q42880252 | A label-free genosensor for BRCA1 related sequence based on impedance spectroscopy |
| Q61796323 | A meiosis-specific BRCA2 binding protein recruits recombinases to DNA double-strand breaks to ensure homologous recombination |
| Q36487269 | A multi-case report of the pathways to and through genetic testing and cancer risk management for BRCA mutation-positive women aged 18-25. |
| Q36922848 | A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function |
| Q38084210 | A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer |
| Q36252996 | Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2. |
| Q35951346 | Advances in breast cancer: pathways to personalized medicine |
| Q33755042 | Analysis of BRCA1and BRCA2 large genomic rearrangements in Sri Lankan familial breast cancer patients and at risk individuals |
| Q57881604 | Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes |
| Q49981052 | Assessment of potential risk factors for breast cancer in a population in Southern Brazil. |
| Q45352459 | Association of BRCA1 promoter methylation with rs11655505 (c.2265C>T) variants and decreased gene expression in sporadic breast cancer. |
| Q33506772 | Association of common variants in mismatch repair genes and breast cancer susceptibility: a multigene study. |
| Q27487849 | BARD1 may be renamed ROW1 because it functions mainly as a REPRESSOR OF WUSCHEL1 |
| Q64948494 | BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance. |
| Q59274104 | BRCA in breast cancer: ESMO Clinical Practice Guidelines |
| Q46009526 | BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile. |
| Q54348841 | BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients. |
| Q39514959 | BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants |
| Q48534893 | BRCA1 and BRCA2 mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway |
| Q36203178 | BRCA1 and BRCA2 mutation testing in Cyprus; a population based study |
| Q37461841 | BRCA1 and microRNAs: emerging networks and potential therapeutic targets |
| Q50108671 | BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation |
| Q37126186 | BRCA1 downregulates the kinase activity of Polo-like kinase 1 in response to replication stress |
| Q35226053 | BRCA1 germline mutation and glioblastoma development: report of cases |
| Q24300290 | BRCA1 is an essential regulator of heart function and survival following myocardial infarction |
| Q93081597 | BRCA1-associated R-loop affects transcription and differentiation in breast luminal epithelial cells |
| Q34773464 | BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families |
| Q84096844 | BRCA1/2 mutations, fertility and the grandmother effect |
| Q53296092 | Breast Cancer Risk from Different Mammography Screening Practices |
| Q48118095 | Breast and ovarian cancer referrals to the ACT Genetic Service: are we meeting guidelines? |
| Q39797410 | Breast cancer after bilateral risk-reducing mastectomy |
| Q43980686 | Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups |
| Q54597972 | Breast cancer incidence and mortality in women under 50 years of age in Brazil. |
| Q35832980 | Breast cancer presentation and therapy in migrant versus native German patients: contrasting and convergent data of a retrospective monocentric study |
| Q50913863 | Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. |
| Q35399596 | Breast cancer risks and risk prediction models |
| Q34949553 | Breast cancer: a neglected disease for the majority of affected women worldwide |
| Q34793556 | CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells |
| Q35656210 | CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice. |
| Q89207885 | Capillary electrophoresis as alternative method to detect tumor genetic mutations: the model built on the founder BRCA1 c.4964_4982del19 variant |
| Q34143322 | Cell death or survival: The double-edged sword of environmental and occupational toxicity. |
| Q39456936 | Cellular Mechanisms Underlying Intertumoral Heterogeneity |
| Q43989797 | Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer |
| Q35091400 | Characterization of an Italian founder mutation in the RING-finger domain of BRCA1. |
| Q33742294 | Chemopreventive Activity of Honokiol against 7, 12 - Dimethylbenz[a]anthracene-Induced Mammary Cancer in Female Sprague Dawley Rats |
| Q41623076 | Clinical Characteristics in Patients with Triple Negative Breast Cancer. |
| Q33896012 | Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer. |
| Q34613122 | Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil |
| Q35695425 | Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries |
| Q50622684 | Concerns about inherited risk of breast cancer prior to diagnosis in Japanese patients with breast complaints |
| Q36656262 | Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer |
| Q37269654 | Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases |
| Q37742898 | DNA damage and decisions: CtIP coordinates DNA repair and cell cycle checkpoints |
| Q37187991 | DNA damage tolerance: a double-edged sword guarding the genome |
| Q34532927 | Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations |
| Q45303666 | Detection of mutations by flow cytometric melting point analysis of PCR products. |
| Q27023165 | Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer |
| Q35622059 | Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes? |
| Q36481648 | Early onset HER2-positive breast cancer is associated with germline TP53 mutations |
| Q37683027 | Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer. |
| Q42609207 | Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1. |
| Q37475917 | Estimation of absolute risk for prostate cancer using genetic markers and family history |
| Q40238343 | Evaluating genetic variants associated with breast cancer risk in high and moderate-penetrance genes in Asians |
| Q34077422 | Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis |
| Q36800754 | Evidence against PALB2 involvement in Icelandic breast cancer susceptibility |
| Q28542563 | Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers |
| Q37019357 | Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis |
| Q34277174 | Evolutionary pathways in BRCA1-associated breast tumors |
| Q37597842 | Exploiting synthetic lethal interactions for targeted cancer therapy |
| Q27015719 | Exploiting the nucleotide substrate specificity of repair DNA polymerases to develop novel anticancer agents |
| Q39851586 | Expression analyses of nuclear receptor genes in breast cancer cell lines exposed to soy phytoestrogens after BRCA2 knockdown by TaqMan Low-Density Array (TLDA). |
| Q37391123 | FANCJ helicase operates in the Fanconi Anemia DNA repair pathway and the response to replicational stress |
| Q85202430 | Family history, BRCA mutations and breast cancer in Vietnamese women |
| Q92002816 | Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets |
| Q36117690 | Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control |
| Q34530426 | Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review |
| Q30728592 | Free the Data |
| Q35869772 | Functional analyses of human DNA repair proteins important for aging and genomic stability using yeast genetics |
| Q33688407 | Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance |
| Q36190966 | Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay. |
| Q37436858 | Functional polymorphisms in the BRCA1 promoter influence transcription and are associated with decreased risk for breast cancer in Chinese women. |
| Q37131303 | Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda |
| Q39699084 | Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents |
| Q36108520 | Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic |
| Q48162236 | Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds |
| Q37181520 | Genetic variation of the brca1 and brca2 genes in macedonian patients |
| Q37360179 | Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes |
| Q34228853 | Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing |
| Q35949522 | Germline BRCA1 mutations increase prostate cancer risk |
| Q64899091 | Germline Missense Variants in BRCA1: New Trends and Challenges for Clinical Annotation. |
| Q55358508 | Hereditary breast and ovarian cancer in Andalusian families: a genetic population study. |
| Q33356511 | Hereditary breast cancer: ever more pieces to the polygenic puzzle |
| Q39657506 | Hereditary breast cancer: the era of new susceptibility genes |
| Q35944416 | Hereditary breast-ovarian cancer syndrome in Russia. |
| Q37147699 | High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients |
| Q57579912 | High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia |
| Q44634590 | High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients |
| Q51786624 | High prevalence of BRCA1 founder mutations in Greek breast/ovarian families. |
| Q47216242 | High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients. |
| Q61448596 | Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins |
| Q37369481 | Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I. |
| Q39144465 | IDP-ASE: haplotyping and quantifying allele-specific expression at the gene and gene isoform level by hybrid sequencing |
| Q34412163 | Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. |
| Q37418120 | Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis |
| Q35623841 | Identifying driver genes in cancer by triangulating gene expression, gene location, and survival data |
| Q37594381 | Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial |
| Q37439146 | Impaired DNA damage response--an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy |
| Q38796779 | Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis |
| Q89892612 | Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes |
| Q34983596 | Inherited predisposition to breast cancer among African American women |
| Q31132980 | Integrating Multi-omics Data to Dissect Mechanisms of DNA repair Dysregulation in Breast Cancer |
| Q100762144 | Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance |
| Q38314132 | Interactomics: toward protein function and regulation |
| Q53171003 | International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. |
| Q42474202 | Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers. |
| Q47880061 | Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan |
| Q46104940 | Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests |
| Q38262476 | Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers. |
| Q36455900 | Linking abnormal mitosis to the acquisition of DNA damage |
| Q55316816 | Long non-coding RNA RP11-552M11.4 promotes cells proliferation, migration and invasion by targeting BRCA2 in ovarian cancer. |
| Q37395490 | Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. |
| Q27309935 | Mapping of Mcs30, a new mammary carcinoma susceptibility quantitative trait locus (QTL30) on rat chromosome 12: identification of fry as a candidate Mcs gene |
| Q33875195 | MicroRNAs discriminate familial from sporadic non-BRCA1/2 breast carcinoma arising in patients ≤35 years. |
| Q34737253 | Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2. |
| Q37286637 | Molecular Characterization and Growth Association of Two Apolipoprotein A-Ib Genes in Common Carp (Cyprinus carpio). |
| Q34727387 | Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). |
| Q64064954 | Novel BRCA2 pathogenic variant c.5219 T > G; p.(Leu1740Ter) in a consanguineous Senegalese family with hereditary breast cancer |
| Q64951109 | Novel Germline Mutations of BRCA1 and BRCA2 in Korean Familial Breast Cancer Patients. |
| Q28741002 | Novel germline PALB2 truncating mutations in African American breast cancer patients |
| Q33355677 | Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals |
| Q36230861 | Novel sequence variants and common recurrent polymorphisms of BRCA2 in Sri Lankan breast cancer patients and a family with BRCA1 mutations |
| Q34307174 | Nuclear nano-morphology markers of histologically normal cells detect the "field effect" of breast cancer |
| Q36251806 | Open biomedical pluralism: formalising knowledge about breast cancer phenotypes |
| Q36252676 | Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers |
| Q36464856 | Outcomes of a systems-level intervention offering breast cancer risk assessments to low-income underserved women |
| Q35795253 | PALB2 mutations in German and Russian patients with bilateral breast cancer |
| Q47157478 | PARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells |
| Q33740638 | PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing |
| Q88605495 | Pathway perturbations in signaling networks: Linking genotype to phenotype |
| Q40321595 | Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population |
| Q64054064 | Portrait of a cancer: mutational signature analyses for cancer diagnostics |
| Q35884235 | Post-transcriptional regulation of BRCA1 through its coding sequence by the miR-15/107 group of miRNAs |
| Q35631178 | Predictive networks: a flexible, open source, web application for integration and analysis of human gene networks |
| Q48163701 | Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers. |
| Q37697803 | Prevalence and impact of founder mutations in hereditary breast cancer in Latin America |
| Q58692157 | Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer |
| Q35619211 | Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece |
| Q37969803 | Prostate cancer genomics, biology, and risk assessment through genome-wide association studies |
| Q61625933 | Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history |
| Q35088480 | Quantitative measurement of serum microRNA-21 expression in relation to breast cancer metastasis in Chinese females |
| Q28249994 | RAD51C germline mutations in breast and ovarian cancer cases from high-risk families |
| Q38903641 | Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes |
| Q47445017 | Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry |
| Q34016479 | Role of 5'- and 3'-untranslated regions of mRNAs in human diseases |
| Q39630929 | Selection for EGFR gene amplification in a breast epithelial cell line with basal-like phenotype and hereditary background. |
| Q36349221 | Sequence Variants of BRCA1 and BRCA2 Genes in Four Iranian Families with Breast and Ovarian Cancer |
| Q46055330 | Serbian high-risk families: extensive results on BRCA mutation spectra and frequency. |
| Q33889288 | Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line |
| Q34400764 | Single nucleotide polymorphisms in noncoding regions of Rad51C do not change the risk of unselected breast cancer but they modulate the level of oxidative stress and the DNA damage characteristics: a case-control study. |
| Q37317360 | Single-nucleotide polymorphisms in PSCA and the risk of breast cancer in a Chinese population |
| Q57577799 | Spectra of BRCA1 and BRCA2 mutations in Korean patients with breast cancer: the importance of whole-gene sequencing |
| Q51737624 | Stellate cells and mesenchymal stem cells in benign mammary stroma are associated with risk factors for breast cancer - an observational study. |
| Q26822592 | Targeting ATM-deficient CLL through interference with DNA repair pathways |
| Q37244880 | Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody |
| Q94452067 | The BRCA2-MEILB2-BRME1 complex governs meiotic recombination and impairs the mitotic BRCA2-RAD51 function in cancer cells |
| Q27861055 | The DNA Damage Response: Making It Safe to Play with Knives |
| Q44039104 | The Potential Contribution of BRCA Mutations to Early Onset and Familial Breast Cancer in Uzbekistan |
| Q37240023 | The korean hereditary breast cancer study: review and future perspectives |
| Q38427087 | The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study. |
| Q36815360 | The role of epigenetic transcriptional regulation in BRCA1-mediated tumor suppression |
| Q33618536 | The validation and clinical implementation of BRCAplus: a comprehensive high-risk breast cancer diagnostic assay |
| Q35916613 | Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy |
| Q35145678 | Triple-negative breast cancers: an updated review on treatment options |
| Q85042592 | Two novel variants in the 3′UTR of the BRCA1 gene in familial breast and/or ovarian cancer |
| Q38229325 | Ubiquitination involved enzymes and cancer |
| Q38288641 | Ugene, a newly identified protein that is commonly overexpressed in cancer and binds uracil DNA glycosylase |
| Q38638531 | Vitamin D Receptor Gene Polymorphism: Association with Susceptibility to Early-Onset Breast Cancer in Iranian, BRCA1/2-Mutation Carrier and non-carrier Patients |
| Q34243783 | Women with familial risk for breast cancer have an increased frequency of aldehyde dehydrogenase expressing cells in breast ductules |
| Q81190552 | [Nasosinusal adenocarcinoma: molecular and genetic analysis by MLPA] |
| Q38733762 | rs15869 at miRNA binding site in BRCA2 is associated with breast cancer susceptibility |
Search more.